In 2023, the cardiac glycosides market in Canada stood at $11.5 million USD PPP. The forecasted values indicate a gradual decline from $11.3 million in 2024 to $10.5 million in 2028. The year-on-year variation shows a consistent decrease of approximately 1.8% annually from 2024 onwards. The compounded annual growth rate (CAGR) over this forecasted period is around -1.8%, reflecting a steady downward trend.
Future trends to watch for:
- Potential advancements in alternative therapies which could further impact cardiac glycosides sales.
- Regulatory changes and new clinical guidelines affecting the prescribing habits of healthcare professionals.
- Innovations in cardiovascular treatments and drug delivery systems that could shift market dynamics.